文献速递消化道肿瘤与早癌消化内镜

局部晚期直肠腺癌放化疗后补救性内镜黏膜下剥离术的技术可行性

Technical feasibility of salvage endoscopic submucosal dissection after chemoradiation for locally advanced rectal adenocarcinoma.
PubMed 文献 · Gastrointest Endosc · 2022-02-17

本研究回顾性比较了2018年7月至2020年8月本机构12例局部晚期直肠癌放化疗后补救性内镜黏膜下剥离术(ESD)与27例无放化疗史的直肠肿瘤标准ESD。补救组整块切除率91.7%、R0切除率66.7%,标准组分别为92.7%和75.0%,两组比较无显著差异;补救组无不良事件,75.0%腺癌放化疗后形态学转变为增生或腺瘤。结论认为补救性ESD技术可行且不良事件率低,可能有助于评估放化疗病理反应并切除残留病变以避免手术。

要点

  • 补救性ESD整块切除率91.7%,R0切除率66.7%,与标准ESD无显著差异。
  • 补救性ESD组无不良事件发生。
  • 75.0%腺癌放化疗后形态学转变为增生或腺瘤,未见超过T1深度的可识别病变。

核心结论

  • 局部晚期直肠癌放化疗后补救性ESD技术可行且不良事件率低。
  • 补救性ESD可能在评估放化疗病理反应方面具有诊断作用,并可能通过切除残留病变避免手术而具有治疗作用。

研究设计与样本

  • 回顾性病历审查,比较2018年7月至2020年8月本机构12例局部晚期直肠癌放化疗后补救性ESD与27例无放化疗史的直肠肿瘤标准ESD。
  • 收集并比较临床因素、影像学、操作过程和病理结果。

主要发现

  • 补救性ESD组放化疗前83.3%的病变初始临床分期为T3。
  • 标准ESD组与补救性ESD组整块切除率分别为92.7%和91.7%(P=1.00)。
  • 标准ESD组与补救性ESD组R0切除率分别为66.7%和75.0%(P=.55)。
  • 补救性ESD组未观察到不良事件。
  • 补救性ESD组75.0%的腺癌放化疗后形态学转变为增生或腺瘤,未见超过T1肿瘤深度的可识别病变。

临床怎么用

  • 作者认为补救性ESD对局部晚期直肠癌技术可行且不良事件率低。
  • 作者认为补救性ESD可能在评估放化疗病理反应方面具有诊断作用,并可能通过切除残留病变避免手术而具有治疗作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The standard treatment of locally advanced rectal cancer is chemoradiation (CRT) followed by proctectomy and adjuvant chemotherapy. However, there is an emerging role for nonsurgical management after CRT or total neoadjuvant therapy (TNT) consisting of CRT and neoadjuvant chemotherapy. Endoscopic submucosal dissection (ESD) after CRT or TNT for rectal cancer, termed "salvage ESD," may be a viable nonsurgical option for carefully selected patients. We aimed to evaluate the feasibility and safety of salvage ESD. METHODS: A retrospective chart review of cases of salvage ESD for locally advanced rectal cancer and standard ESD for rectal tumors without prior CRT from July 2018 to August 2020 at our institution was performed. Clinical factors and imaging, procedural, and pathology results were collected and compared. RESULTS: Twelve salvage ESD cases were compared with 27 standard ESD cases. Before CRT, 83.3% of lesions in the salvage ESD group were initially clinically staged as T3. The en-bloc resection rates were 92.7% and 91.7% (P = 1.00) and R0 resection rates 66.7% and 75.0% (P = .55) for the standard and salvage groups, respectively. In the salvage ESD group, no adverse events were observed, and 75.0% of the adenocarcinomas in the salvage ESD group had morphologically changed to hyperplasia or adenoma after CRT, with no identifiable lesions greater than T1 tumor depth. CONCLUSIONS: Salvage ESD for locally advanced rectal cancer is technically feasible with low adverse event rates. There may be a diagnostic role in salvage ESD in assessing pathologic response to CRT and a possible therapeutic role in resection of residual lesions with the potential to avoid surgery.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Leung G, Nishimura M, Hingorani N, et al. Technical feasibility of salvage endoscopic submucosal dissection after chemoradiation for locally advanced rectal adenocarcinoma. Gastrointest Endosc. 2022. PMID: 35183541. doi:10.1016/j.gie.2022.02.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。